Testing duvakitug for long-term ulcerative colitis control
Treatments studied
Part of Digestive system clinical trials.
This study tests the long-term safety and effectiveness of an experimental drug called duvakitug in people with moderate to severe ulcerative colitis. It is for those who have already responded well to treatment in a previous study and need ongoing care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old (or 16 to 17 and fully developed)
- You have moderate to severe ulcerative colitis
- You completed a previous study (SUNSCAPE-1) and had a good response and a follow-up scope
- Or, you completed the main part of this study or another related study
- You do not have any medical or personal issues that would make the study unsafe for you
- You are not allergic to duvakitug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
This study tests two experimental drugs, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if these drugs can help control the disease.
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
This study tests whether adding a special turmeric supplement (CurQD) to the standard treatment vedolizumab helps calm moderate-to-severe ulcerative colitis more than vedolizumab alone. It may be a good option if your colitis is active despite current medications.
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.